Results
Twelve patients with a median age of 15 (12.9-33.2) years were enrolled
(7 with Ewing sarcoma; 5 with osteosarcoma); all were evaluable for
toxicity. At dose level 1, three of six patients developed first cycle
DLT: grade 3 epistaxis; grade 3 transaminitis; prolonged grade 2
thrombocytopenia. Six patients were enrolled on dose level -1B
(interrupted cabozantinib, given days 8-21), with one first cycle DLT
(grade 3 pneumothorax) observed. Of the 10 response evaluable patients,
one had partial response (Ewing sarcoma), seven had stable disease, and
two had progressive disease.